E

The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15

Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma

November 11, 2019
E

Waves and waves of T cells

What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy

June 27, 2019
E

Navigating new opportunities in the IL-2 space

How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?

June 26, 2019
E

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019
E

Alternative approaches to targeting cytokines

Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?

June 19, 2019
E

New developments in cytokines as immune modulators

New insights emerging from research on cytokines as an effective way to induce anti tumour immunity

January 31, 2019
E

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

November 13, 2018
E

An analysis of Nektar’s latest PIVOT data and pipeline update

Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma

November 12, 2018
E

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018
E

Armored CAR-T cell therapies and commercial threats from the East

On launched products, armored CARs and the potential threat from China

August 16, 2018
E

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018
E

The Potential for Cytokines in Cancer Immunotherapy

The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...

June 18, 2018
E

How should we interpret the NKTR–214 data presented at ASCO?

What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?

June 14, 2018
E

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018
E

Bench to bedside and back again

A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types

May 1, 2018
E

Targeting TGF-β and the tumour microenvironment

A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy

April 30, 2018
E

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018
E

Update on cytokines as novel cancer immunotherapy

A look at innate approaches to stimulating the immune system including IL-15 agonists

February 21, 2018
E

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017
E
National Harbor from Gaylord Hotel

SITC17 – Final Look at what to watch out for

Final SITC17 Preview and a look at key talks now that the abstracts are available.

November 8, 2017
E

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017
E

SITC 2016 Can Nektar Boost Checkpoint Performance

Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...

November 16, 2016